1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

25 Apr 2023
Admin
News Article

Us Fda Approves Novartis Millburn Facility For Us Commercial Production Of Pluvicto

Novartis Has Received Us Food And Drug Administration (Fda) Approval To Begin Supplying Pluvicto For Us Commercial Use From The Novartis Radioligand Therapy (Rlt) Manufacturing Facility In Millburn, New Jersey. Production Will Begin In The Coming Weeks And Ramp Up Gradually.The Site Is Expected To Contribute Meaningfully To Supply And Sales In The Third Quarter, After The Anticipated Approval Of Additional Lines At The Site. Capacity Should Continue To Increase Through The Second Half Of This Year, Helping To Ensure Stable, Reliable Supply To Patients.The Rlt Manufacturing Facility In Ivrea, Italy, Will Continue To Supply The Us Market, And Further Capacity Expansion Is Underway At The Site.A New Facility In Indianapolis, Indiana, Is Nearing Completion, And Is Expected To Open As Soon As The End Of This Year. In Addition, Novartis Has Received Approval For The Zaragoza, Spain, Site To Supply The Eu Market. We Expect This Site To Ramp Up Gradually Over The Coming Months.With These Sites, A Capacity Of At Least 250K Doses Of Pluvicto Annually Is Targeted In 2024+

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!